164 related articles for article (PubMed ID: 28933644)
1. Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells.
Chen Q; Nie J; Huang W; Jiao Y; Li L; Zhang T; Zhao J; Wu H; Wang Y
Hum Vaccin Immunother; 2018 Jan; 14(1):199-208. PubMed ID: 28933644
[TBL] [Abstract][Full Text] [Related]
2. Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells.
Sarzotti-Kelsoe M; Daniell X; Todd CA; Bilska M; Martelli A; LaBranche C; Perez LG; Ochsenbauer C; Kappes JC; Rountree W; Denny TN; Montefiori DC
J Immunol Methods; 2014 Jul; 409():147-60. PubMed ID: 24607608
[TBL] [Abstract][Full Text] [Related]
3. Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China.
Nie J; Wang W; Wen Z; Song A; Hong K; Lu S; Zhong P; Xu J; Kong W; Li J; Shang H; Ling H; Ruan L; Wang Y
J Virol Methods; 2012 Nov; 185(2):267-75. PubMed ID: 22796285
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
[TBL] [Abstract][Full Text] [Related]
5. Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.
McLinden RJ; Labranche CC; Chenine AL; Polonis VR; Eller MA; Wieczorek L; Ochsenbauer C; Kappes JC; Perfetto S; Montefiori DC; Michael NL; Kim JH
PLoS One; 2013; 8(11):e77756. PubMed ID: 24312168
[TBL] [Abstract][Full Text] [Related]
6. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
Montefiori DC; Karnasuta C; Huang Y; Ahmed H; Gilbert P; de Souza MS; McLinden R; Tovanabutra S; Laurence-Chenine A; Sanders-Buell E; Moody MA; Bonsignori M; Ochsenbauer C; Kappes J; Tang H; Greene K; Gao H; LaBranche CC; Andrews C; Polonis VR; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Kaewkungwal J; Self SG; Berman PW; Francis D; Sinangil F; Lee C; Tartaglia J; Robb ML; Haynes BF; Michael NL; Kim JH
J Infect Dis; 2012 Aug; 206(3):431-41. PubMed ID: 22634875
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
Li M; Gao F; Mascola JR; Stamatatos L; Polonis VR; Koutsoukos M; Voss G; Goepfert P; Gilbert P; Greene KM; Bilska M; Kothe DL; Salazar-Gonzalez JF; Wei X; Decker JM; Hahn BH; Montefiori DC
J Virol; 2005 Aug; 79(16):10108-25. PubMed ID: 16051804
[TBL] [Abstract][Full Text] [Related]
8. Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1.
Kim JH; Pitisuttithum P; Kamboonruang C; Chuenchitra T; Mascola J; Frankel SS; DeSouza MS; Polonis V; McLinden R; Sambor A; Brown AE; Phonrat B; Rungruengthanakit K; Duliege AM; Robb ML; McNeil J; Birx DL;
AIDS Res Hum Retroviruses; 2003 Sep; 19(9):807-16. PubMed ID: 14585211
[TBL] [Abstract][Full Text] [Related]
9. Impact of host cell variation on the neutralization of HIV-1 in vitro.
Polonis VR; Schuitemaker H; Bunnik EM; Brown BK; Scarlatti G
Curr Opin HIV AIDS; 2009 Sep; 4(5):400-7. PubMed ID: 20048704
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination.
Polonis VR; Brown BK; Rosa Borges A; Zolla-Pazner S; Dimitrov DS; Zhang MY; Barnett SW; Ruprecht RM; Scarlatti G; Fenyö EM; Montefiori DC; McCutchan FE; Michael NL
Virology; 2008 Jun; 375(2):315-20. PubMed ID: 18367229
[TBL] [Abstract][Full Text] [Related]
11. International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.
Ozaki DA; Gao H; Todd CA; Greene KM; Montefiori DC; Sarzotti-Kelsoe M
PLoS One; 2012; 7(1):e30963. PubMed ID: 22303476
[TBL] [Abstract][Full Text] [Related]
12. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.
Gilbert P; Wang M; Wrin T; Petropoulos C; Gurwith M; Sinangil F; D'Souza P; Rodriguez-Chavez IR; DeCamp A; Giganti M; Berman PW; Self SG; Montefiori DC
J Infect Dis; 2010 Aug; 202(4):595-605. PubMed ID: 20608874
[TBL] [Abstract][Full Text] [Related]
13. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
14. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
Brown BK; Wieczorek L; Sanders-Buell E; Rosa Borges A; Robb ML; Birx DL; Michael NL; McCutchan FE; Polonis VR
Virology; 2008 Jun; 375(2):529-38. PubMed ID: 18433824
[TBL] [Abstract][Full Text] [Related]
15. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.
Sarzotti-Kelsoe M; Bailer RT; Turk E; Lin CL; Bilska M; Greene KM; Gao H; Todd CA; Ozaki DA; Seaman MS; Mascola JR; Montefiori DC
J Immunol Methods; 2014 Jul; 409():131-46. PubMed ID: 24291345
[TBL] [Abstract][Full Text] [Related]
16. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
17. Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India.
Hussain SI; Panneerselvam N; Solomon S; Solomon SS; Adam K; Chandrasekaran E; Montefiori DC; Pachamuthu B
J Int Assoc Provid AIDS Care; 2017; 16(2):201-208. PubMed ID: 23422744
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
[TBL] [Abstract][Full Text] [Related]
19. Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones.
Chenine AL; Merbah M; Wieczorek L; Molnar S; Mann B; Lee J; OʼSullivan AM; Bose M; Sanders-Buell E; Kijak GH; Herrera C; McLinden R; OʼConnell RJ; Michael NL; Robb ML; Kim JH; Polonis VR; Tovanabutra S
J Acquir Immune Defic Syndr; 2018 Jul; 78(3):348-355. PubMed ID: 29528942
[TBL] [Abstract][Full Text] [Related]
20. The importance of antibody isotype in HIV-1 virus capture assay and in TZM-bl neutralization.
Peachman KK; Wieczorek L; Matyas GR; Polonis VR; Alving CR; Rao M
Viral Immunol; 2010 Dec; 23(6):627-32. PubMed ID: 21142448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
